Propanc Biopharma plans Phase 1b first-in-human PRP trial in advanced solid tumors starting February 2027

PUBT · 1d ago
Propanc Biopharma plans Phase 1b first-in-human PRP trial in advanced solid tumors starting February 2027
  • Propanc Biopharma outlined plans to start a first-in-human Phase 1b study of PRP in February 2027.
  • The planned trial targets advanced solid tumors, with initial focus on pancreatic cancer, ovarian cancer, and refractory prostate cancer.
  • PRP has not reported human efficacy results yet; the update centers on preclinical findings and a clinical-development timeline.
  • Management framed PRP as a potential add-on or maintenance approach alongside emerging RAS inhibitors to improve durability of responses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160830PRIMZONEFULLFEED9826906) on September 16, 2026, and is solely responsible for the information contained therein.